Children’s Cancer Institute shared on LinkedIn:
“The mutations that drive childhood cancers are different from those driving adult cancers, yet children still rely heavily on drugs and treatments repurposed from adult treatments. These can cause lasting health problems, including secondary cancers, affecting both their quality and length of life.
In this episode of the New Horizons podcast with Heather Robertson from Science Alliance, Antoine De Weck explains the scientific and commercial barriers behind this treatment gap, and how the think initiative at Children’s Cancer Institute is working to develop more targeted treatments specifically for children.
You can also read: How Lewis Hamilton and F1 Helped Raise £275K for Childhood Cancer Research
